BSGM - BioSig Technologies Inc Stock Price, Fair Value and News

1.65USD+0.04 (+2.48%)Market Closed

Market Summary

USD1.65+0.04

Market Closed

2.48%

BSGM Stock Price

View Fullscreen

BSGM RSI Chart

BSGM Valuation

Market Cap

18.5M

Price/Earnings (Trailing)

-0.64

Price/Sales (Trailing)

1.0K

EV/EBITDA

-0.65

Price/Free Cashflow

-1.06

BSGM Price/Sales (Trailing)

BSGM Profitability

Operating Margin

-1005.56%

EBT Margin

-159388.89%

Return on Equity

972.08%

Return on Assets

-1.6K%

Free Cashflow Yield

-94.71%

BSGM Fundamentals

BSGM Revenue

Revenue (TTM)

18.0K

Rev. Growth (Yr)

-91.11%

Rev. Growth (Qtr)

1.1K%

BSGM Earnings

Earnings (TTM)

-29.1M

Earnings Growth (Yr)

13.32%

Earnings Growth (Qtr)

-31.5%

Breaking Down BSGM Revenue

Last 7 days

32%

Last 30 days

1.2%

Last 90 days

166.1%

Trailing 12 Months

-88.9%

How does BSGM drawdown profile look like?

BSGM Financial Health

Current Ratio

0.12

BSGM Investor Care

Shares Dilution (1Y)

58.87%

Diluted EPS (TTM)

-3.53

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	219.0K	152.0K	85.0K	18.0K
2022	402.3K	363.5K	324.8K	286.0K
2021	0	0	0	441.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of BioSig Technologies Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 01, 2024	hrkac frederick	acquired	-	-	500,000	-
Nov 30, 2023	londoner kenneth l	acquired	-	-	219,700	chief executive officer
Nov 30, 2023	fleming gray	acquired	-	-	131,900	chief commercial officer
Nov 30, 2023	sieckhaus john	acquired	-	-	92,300	chief operating officer
Aug 15, 2023	weild iv david	acquired	-	-	16,000	-
Aug 15, 2023	barry james j	acquired	-	-	12,000	-
Aug 15, 2023	klein james l	acquired	-	-	16,000	-
Aug 15, 2023	foley donald e	acquired	-	-	16,000	-
Aug 15, 2023	hrkac frederick	acquired	-	-	16,000	-
Aug 15, 2023	gallagher patrick joseph	acquired	-	-	12,000	-

Which funds bought or sold BSGM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-8,362	-	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	28,962	28,962	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	142	142	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-36,696	-	-%
May 15, 2024	Royal Bank of Canada	new	-	-	-	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-6,000	-	-%
May 15, 2024	SILVERCREST ASSET MANAGEMENT GROUP LLC	sold off	-100	-4,750	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-16,658	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	4,658	4,658	-%
May 15, 2024	MORGAN STANLEY	new	-	2,103	2,103	-%

Are Funds Buying or Selling BSGM?

Are funds buying BSGM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BSGM

No. of Funds

Unveiling BioSig Technologies Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	6.36%	5,600,000	SC 13G
Jul 12, 2021	blackrock inc.	1.4%	454,144	SC 13G/A
Feb 02, 2021	blackrock inc.	5.7%	1,733,676	SC 13G

Recent SEC filings of BioSig Technologies Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	NT 10-Q	NT 10-Q
May 07, 2024	8-K	Current Report
May 07, 2024	8-K	Current Report
May 07, 2024	8-K	Current Report
May 03, 2024	8-K	Current Report
May 02, 2024	8-K	Current Report
Apr 16, 2024	10-K	Annual Report
Apr 02, 2024	NT 10-K	NT 10-K
Mar 18, 2024	8-K	Current Report
Mar 12, 2024	8-K	Current Report

Peers (Alternatives to BioSig Technologies Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

BioSig Technologies Inc News

Latest updates

BioSig Technologies Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)												(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	1100.0%	12,000	1,000	45,667	90,333	135,000	135,000	8,000	8,000	8,000	108,000	207,000	118,000
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	38,000	62,000	99,000
Gross Profit	1100.0%	12,000	1,000	-	-	108,000	105,000	8,000	8,000	8,000	70,000	145,000	19,000
Operating Expenses	52.5%	6,179,000	4,052,000	10,908,000	7,391,000	7,106,000	6,591,000	5,724,000	8,073,000	9,007,000	7,871,000	8,196,000	8,579,000
S&GA Expenses	74.4%	4,910,000	2,815,000	9,107,000	6,245,000	5,903,000	4,774,000	4,302,000	6,401,000	7,597,000	6,505,000	6,480,000	7,271,000
R&D Expenses	3.4%	1,184,000	1,145,000	1,709,000	1,062,000	1,116,000	1,700,000	1,351,000	1,617,000	1,352,000	1,315,000	1,667,000	1,266,000
EBITDA Margin	-358.0%	-1,573	-343	-208	-119	-94.29	-89.29	-81.96	-79.93	-74.05	-	-	-
Interest Expenses	0%	1,000	1,000	3,000	4,000	2,000	1,000	-	-	-	1,000	-	1,000
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-51.3%	-6,128,000	-4,050,000	-11,130,000	-7,382,000	-6,996,000	-6,485,000	-5,716,000	-8,065,000	-8,999,000	-7,247,000	-8,051,000	-8,559,000
EBT Margin	-358.4%	-1,593	-347	-210	-121	-95.32	-90.12	-82.61	-80.45	-74.50	-	-	-
Net Income	-31.5%	-6,005,500	-4,567,000	-11,130,000	-7,382,000	-6,928,500	-6,372,000	-5,716,000	-8,065,000	-8,349,000	-7,253,000	-8,051,000	-8,559,000
Net Income Margin	-357.7%	-1,615	-353	-209	-120	-94.69	-87.77	-80.83	-78.85	-73.04	-	-	-
Free Cashflow	24.8%	-2,946,000	-3,917,000	-4,972,000	-5,693,000	-4,172,000	-4,997,000	-6,708,000	-5,996,000	-5,875,000	-6,974,000	-6,971,000	-7,121,000

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-43.0%	1,798	3,154	4,050	5,197	4,110	5,015	9,590	4,110	15,519	21,673	18,027	24,516	30,386	34,953	39,812	17,841	14,217	14,221	12,062	11,904	4,997
Current Assets	-49.8%	528	1,051	1,987	2,150	1,128	3,089	7,736	11,002	13,894	19,999	16,949	23,334	29,337	33,893	38,652	16,560	12,828	12,883	10,640	11,090	4,629
Cash Equivalents	-51.2%	190	389	1,252	1,412	357	887	5,077	8,665	11,659	17,535	15,504	22,475	28,268	32,748	36,927	15,500	12,109	12,309	10,334	10,934	4,450
Inventory	-100.0%	-	219	189	345	336	1,691	2,026	2,026	1,881	1,881	731	650	800	806	800	800	600	-	-	-	-
Net PPE	-14.2%	509	593	621	630	665	685	596	656	652	557	388	381	289	188	175	185	180	102	78.00	180	44.00
Liabilities	14.2%	4,685	4,104	3,614	3,182	3,713	3,076	2,508	3,027	2,954	2,993	3,405	3,953	5,109	-	-	-	-	1,589	1,882	1,236	1,198
Current Liabilities	17.2%	4,582	3,911	3,332	2,814	3,261	2,540	1,899	2,709	2,576	2,571	3,383	3,896	5,108	4,960	3,607	1,584	2,030	1,213	1,414	1,009	1,198
Shareholder's Equity	-Infinity%	-2,992	-	331	1,910	313	1,834	6,977	9,410	12,460	18,575	14,517	20,458	25,172	29,866	36,012	15,851	11,661	12,418	9,965	10,193	3,324
Retained Earnings	-2.5%	-245,015	-238,966	-234,399	-223,306	-215,974	-209,016	-202,644	-196,885	-188,922	-180,278	-173,025	-165,324	-157,005	-146,712	-135,310	-116,122	-104,787	-89,994	-84,551	-76,601	-70,731
Additional Paid-In Capital	1.8%	241,988	237,727	234,568	225,215	216,282	210,792	209,456	206,240	201,127	198,380	187,136	185,168	181,344	175,228	168,499	131,340	115,910	101,484	94,495	86,466	74,039
Shares Outstanding	14.1%	9,040	7,924	7,346	6,686	5,505	4,031	4,481	3,956	3,557	3,525	3,221	3,211	-	-	-	-	-	-	-	-	-
Minority Interest	-75.2%	26.00	105	89.00	-66.00	-21.00	12.00	120	16.00	219	438	374	582	802	1,320	2,794	607	515	406	-	-	-
Float	-	-	-	76,956	-	-	-	28,094	-	-	-	108,511	-	-	-	182,303	-	-	-	146,426	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	23.1%	-2,942	-3,828	-4,895	-5,648	-4,114	-4,947	-6,703	-5,941	-5,731	-6,758	-6,919	-6,991	-6,104	-6,274	-8,281	-5,942	-3,901	-3,939	-4,119	-3,522	-2,969
Share Based Compensation	502.8%	1,446	-359	4,742	2,149	1,709	537	166	2,000	4,597	63.00	611	2,519	-1,859	175	429	4,413	-	418	477	2,670	4,208
Cashflow From Investing	93.3%	-4.00	-60.00	-77.00	-45.00	-58.00	-50.00	-5.00	-55.00	-144	-216	-52.00	-130	-27.00	-32.00	-8.00	-20.00	-90.11	-38.06	-83.81	-73.02	-57.31
Cashflow From Financing	-9.2%	2,747	3,025	4,812	6,748	3,642	807	3,120	3,002	-1.00	9,005	-	1,328	1,650	2,127	29,716	9,354	3,792	5,952	3,604	10,079	197

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BSGM Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 18	$ 286
Cost of revenue		57
Gross profit	18	229
Operating expenses:
Research and development	5,092	5,821
General and administrative	23,077	21,380
Depreciation and amortization	361	293
Total operating expenses	28,530	27,494
Loss from operations	(28,512)	(27,265)
Other income (expense):
Interest income, net	9	3
Other income (expense), net:	(187)
Loss before income taxes	(28,690)	(27,262)
Income taxes (benefit)
Net loss	(28,690)	(27,262)
Non-controlling interest	(351)	210
Net loss attributable to BioSig Technologies, Inc.	(29,041)	(27,052)
Preferred stock dividend	(9)	(9)
Preferred stock deemed dividend		(210)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (29,050)	$ (27,271)
Net loss per common share, basic	$ (3.95)	$ (6.33)
Net loss per common share, diluted	$ (3.95)	$ (6.33)
Weighted average number of common shares outstanding, basic	7,351,794	4,307,244
Weighted average number of common shares outstanding, diluted	7,351,794	4,307,244
Product [Member]
Revenue:
Total revenue		$ 254
Service [Member]
Revenue:
Total revenue	$ 18	$ 32

BSGM Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 190	$ 357
Accounts receivable	24	9
Employee advance	5
Inventory, short term		336
Net investment in leases, short term	103	101
Prepaid expenses and vendor deposits	206	325
Total current assets	528	1,128
Property and equipment, net	509	665
Right-to-use assets, net	412	705
Other assets:
Inventory, long term		1,141
Net investment in leases, long term	17	120
Patents, net	288	307
Other assets	44	44
Total assets	1,798	4,110
Current liabilities:
Accounts payable and accrued expenses, including $30 and $120 to related parties as of December 31, 2023 and 2022, respectively	4,116	2,852
Customer deposits	16
Deferred revenue, short term		5
Dividends payable	101	91
Lease liability, short term	349	313
Total current liabilities	4,582	3,261
Lease liability, long term	103	452
Total long-term liabilities	103	452
Total liabilities	4,685	3,713
Commitments and contingencies (Note 12)
Series C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; liquidation preference of $105 as of December 31, 2023 and 2022	105	105
Equity (Deficit):
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred Stock. 105 shares of Series C outstanding as of December 31, 2023 and 2022 (see above)
Common stock, $0.001 par value, authorized 200,000,000 shares, 9,040,043 and 5,505,068 issued and outstanding as of December 31, 2023 and 2022, respectively	9	5
Additional paid in capital	241,988	216,282
Accumulated deficit	(245,015)	(215,974)
Total stockholders’ equity (deficit) attributable to BioSig Technologies, Inc.	(3,018)	313
Non-controlling interest	26	(21)
Total equity (deficit)	(2,992)	292
Total liabilities and equity (deficit)	$ 1,798	$ 4,110

About BioSig Technologies Inc

BioSig Technologies, Inc., together with its subsidiaries, a medical device company, commercializes advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias. The company offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for catheter ablation procedures for arrhythmias. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

CEO	Mr. Kenneth L. Londoner M.B.A., MBA
WEBSITE	biosig.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	47

BioSig Technologies Inc Frequently Asked Questions

What is the ticker symbol for BioSig Technologies Inc? What does BSGM stand for in stocks?

BSGM is the stock ticker symbol of BioSig Technologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioSig Technologies Inc (BSGM)?

As of Fri May 17 2024, market cap of BioSig Technologies Inc is 18.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BSGM stock?

You can check BSGM's fair value in chart for subscribers.

What is the fair value of BSGM stock?

You can check BSGM's fair value in chart for subscribers. The fair value of BioSig Technologies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioSig Technologies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BSGM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioSig Technologies Inc a good stock to buy?

The fair value guage provides a quick view whether BSGM is over valued or under valued. Whether BioSig Technologies Inc is cheap or expensive depends on the assumptions which impact BioSig Technologies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BSGM.

What is BioSig Technologies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BSGM's PE ratio (Price to Earnings) is -0.64 and Price to Sales (PS) ratio is 1.03 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BSGM PE ratio will change depending on the future growth rate expectations of investors.